Search results for "Coronavirus"
We must rise with the occasion and save our country
The current COVID-19 pandemic requires that ACP carefully craft public policies not only for how care is organized and delivered on the front lines but also for helping physicians save patients while keeping themselves safe as well.
https://immattersacp.org/archives/2020/05/we-must-rise-with-the-occasion-and-save-our-country.htm
1 May 2020
New COVID-19 vaccine authorized; reviews analyze myocarditis, drug treatments
The FDA gave the Novavax COVID-19 vaccine emergency use authorization for adults. One recent review found lower myocarditis risk with the Pfizer-BioNTech vaccine than the Moderna vaccine, and another looked at the strength of evidence supporting COVID-19 drug treatments.
https://immattersacp.org/weekly/archives/2022/07/19/4.htm
19 Jul 2022
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://immattersacp.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022
IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir
The Infectious Diseases Society of America (IDSA) listed six steps to help clinicians prescribe the COVID-19 medication while minimizing interaction risks. Other recent research looked at neuropsychiatric conditions after COVID-19 and hospital profits during the pandemic.
https://immattersacp.org/weekly/archives/2022/05/17/2.htm
17 May 2022
Oral medications for COVID-19 underused among socially vulnerable, CDC study finds
By late May, the rate of prescriptions for molnupiravir and nirmatrelvir/ritonavir was twice as high in the highest-income U.S. ZIP codes as in the lowest, research showed. A CDC webinar on June 28 will discuss efforts to equitably distribute these treatments.
https://immattersacp.org/weekly/archives/2022/06/28/2.htm
28 Jun 2022
Nirmatrelvir/ritonavir rarely leads to rebound, doesn't help average-risk patients, studies find
A retrospective analysis found that symptom rebound occurred in less than 1% of high-risk COVID-19 patients treated with nirmatrelvir/ritonavir, while the manufacturer reported that the drug didn't show significant benefit in average-risk patients.
https://immattersacp.org/weekly/archives/2022/06/21/2.htm
21 Jun 2022
Fourth vaccine dose 62% effective against severe COVID-19 in month after receipt
Retrospective data from Israel showed that in people ages 60 years and older, an additional booster dose of the Pfizer-BioNTech COVID-19 vaccine was 55% effective against symptomatic disease and 68% effective against hospitalization.
https://immattersacp.org/weekly/archives/2022/04/19/4.htm
19 Apr 2022
New reports on early symptoms, cardiac complications of COVID-19
Loss of smell and taste have been suggested as possible early symptoms of COVID-19, and cardiac complications appear to be a significant issue among infected patients with or without baseline cardiovascular disease.
https://immattersacp.org/weekly/archives/2020/03/31/2.htm
31 Mar 2020
Studies examine persistent symptoms of COVID-19
A U.K. study found that COVID-19 vaccination after infection may help persistent symptoms, while a U.S. study found that the burden of such symptoms appears high.
https://immattersacp.org/weekly/archives/2022/05/24/5.htm
24 May 2022
Register now for ACP and Annals of Internal Medicine's COVID-19 Forum VIII: Outpatient Evaluation and Management of Patients with COVID-19
During the Feb. 9 virtual live event, a panel of experts will discuss appropriate COVID-19 testing, quarantine and isolation periods, management of symptoms, and recommended treatments in the outpatient setting.
https://immattersacp.org/weekly/archives/2022/02/01/2.htm
1 Feb 2022